A randomized, double-blind, placebo-controlled evaluation of weekly etaquine for chemo-suppression of Plasmodium falciparum in semi-immune adults living in the Kassena-Nankana district of northern Ghana

Location          :Navrongo - Ghana

Investigators  :Greg Utz, F. Binka, S. Owusu-Agyei, Kevin Baird
                       Kojo Koram, Francis Nkrumah, Steve Hoffman

Collaboration   :Navrongo Health Research Centre, Navrongo. Ghana.
                       Noguchi Memorial Institute for Medical Research
                       U.S. Naval Medical Research Unit #3
                       Naval Medical Research Institute
                       US Army Medical Material Development Activity (USAMMDA)
                       

Funding             :US Navy

Period Covered:

OBJECTIVES

1.      To determine the chemosuppressive efficacy of weekly Etaquine at a range between 31 and 250 mg in preventing Plasmodium falciparum parasitemia compared to placebo and secondarily to mefloquine in subjects semi-immune to malaria.

2.      To establish the minimum effective prophylactic dose of weekly Etaquine and assess the tolerability of that dose